GSK considers licensing Cann’s CBD capsule

11 April 2022 - Deborah Wilkes

Premium

GlaxoSmithKline (GSK) Consumer Healthcare is considering a licensing deal for Cann Group’s cannabidiol (CBD) capsule in Australia and other markets worldwide.

Click tags below for more information on topics:

GlaxoSmithKline CBD

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: